Cash Flow Statement

Amortization of Deferred Charges Amortization of Deferred Charges Amortizatization of Intangibles Amortizatization of Intangibles Asset Writedowns and Impairment Asset Writedowns and Impairment Capital Expenditures Capital Expenditures Cash from Financing Activities Cash from Financing Activities Cash from Operations Cash from Operations Change in Account Payables Change in Account Payables Change in Accured Expenses Change in Accured Expenses Change in Cash Change in Inventory Change in Inventory Change in Receivables Change in Receivables Exchange Rate Effect Exchange Rate Effect Free Cash Flow Free Cash Flow Gains from Investment Securities Gains from Investment Securities Gains from Sales and Divestitures Gains from Sales and Divestitures Long-Term Debt Issuances Net Cash Flow Net Cash Flow Net Income Non-cash Items Non-cash Items Other Working Capital Changes Other Working Capital Changes Other financing activities Other financing activities Share-based Compensation Share-based Compensation Shares Issued Shares Repurchased

Daily Values

Growth Metrics

Others

Fennec Pharmaceuticals (FENC) Asset Writedowns and Impairment (2024 - 2025)

Fennec Pharmaceuticals filings provide 2 years of Asset Writedowns and Impairment readings, the most recent being $1.3 million for Q4 2025.

On a quarterly basis, Asset Writedowns and Impairment rose 141.79% to $1.3 million in Q4 2025 year-over-year; TTM through Dec 2025 was $773000.0, a 125.04% increase, with the full-year FY2025 number at $773000.0, up 49.52% from a year prior.
Asset Writedowns and Impairment hit $1.3 million in Q4 2025 for Fennec Pharmaceuticals, up from -$1.7 million in the prior quarter.
In the past five years, Asset Writedowns and Impairment ranged from a high of $1.3 million in Q4 2025 to a low of -$3.1 million in Q4 2024.